The Body as Asset Class: Longevity Industry Guide for SMEs

The Body as Asset Class

How Silicon Valley turned the oldest human fear into the newest status symbol — and what it means for the rest of us

---

There is a particular kind of ambition that has always distinguished the very wealthy from merely the successful: the refusal to accept conditions that everyone else simply tolerates. Bad neighborhoods, bad schools, bad hospitals. Money has always been a hedge against discomfort. Now it is becoming a hedge against death.

This is not a metaphor.

Over the past decade, a convergence of biotechnology, artificial intelligence, and staggering private capital has produced a new category of product — one that doesn’t promise a better life so much as a longer one. The longevity industry, broadly defined, was estimated at roughly $23 billion in 2025 and is projected to exceed $63 billion by 2035, according to Market Research Future. Those numbers come from sector analysts, not peer-reviewed science, and should be read as indicators of investor appetite as much as anything else. But the underlying dynamic they’re pointing to is real: for the first time in history, the serious pursuit of human longevity has the attention of serious money.

At the frontier, it looks less like a healthcare market and more like a private members’ club — one with a very specific dress code. Good biomarkers required.

---

A Problem Worth Solving

The pitch is seductive precisely because it’s built on real science.

Aging, researchers now understand, is not simply the passage of time. It’s a biological process — marked by the accumulation of senescent cells, the erosion of telomeres, the deterioration of mitochondrial function and epigenetic regulation. These are measurable phenomena. And if something can be measured, the thinking goes, it can be intervened upon.

This logic has attracted serious people and serious capital. In 2013, Google co-founder Larry Page launched Calico Labs, a research company focused on the biology of aging. Altos Labs launched in 2022 with $3 billion in initial funding, recruited Nobel laureates, and set out to pursue cellular reprogramming — the idea that you can restore a cell to a younger state by chemically altering its epigenetic marks.

Among its reported investors is Jeff Bezos. Sam Altman put $180 million into Retro Biosciences. Peter Thiel has backed multiple aging-focused ventures and declared, in terms that have become something of a Silicon Valley credo, that death is a problem to be solved, not a fate to accept.

The science here is not trivial. The work on partial cellular reprogramming — using what are called Yamanaka factors to nudge cells back toward a more youthful state — is some of the most interesting biology happening right now. The question is not whether it matters. It does. The question is who gets access to whatever it produces, and when.

---

The Clinic as Status Object

While the labs work on timelines measured in decades, a parallel industry has emerged to serve the impatient.

The luxury longevity clinic — part diagnostic center, part performance facility, part spa — has become one of the more revealing artifacts of the current moment. These are not hospitals.

They don’t treat disease so much as preempt it, offering comprehensive preventive assessments built around advanced imaging, continuous biomarker monitoring, and data-driven personalization. The framing is always the same: this isn’t sick care, it’s health optimization.

Dr. Peter Attia, a physician trained at Stanford and Johns Hopkins, has built perhaps the most influential brand in this space. His practice, Early Medical, operates around what he calls “Medicine 3.0” — a framework that emphasizes aggressive prevention over reactive treatment, and treats the goal of medicine as maximizing not just lifespan but healthspan, the period of life spent in full functional health.

His affiliated venture Biograph charges $7,500 annually for a membership that includes a six-hour initial visit, a full-body MRI, continuous glucose monitoring, and analysis of more than 1,000 data points across 20-plus evaluations; a “Black” membership runs $15,000 a year. In early 2025, the clinic announced an expansion from Silicon Valley to New York City.

Then there is Bryan Johnson. Johnson is harder to classify. A tech entrepreneur who sold his payments company to PayPal for $800 million in 2013, he has spent, by his own account, roughly $2 million a year on what he calls Blueprint — a protocol involving more than 100 daily supplements, a strict plant-based diet, round-the-clock biomarker tracking, and various experimental interventions.

In February 2026, he announced “Immortals,” offering his exact protocol to outside clients at $1 million a year, with three spots available. He claims his biological age has reversed by more than five years, though those claims rest on self-reported data and have not been independently validated.

Johnson’s critics include serious scientists. One prominent hepatologist publicly called him a “modern-day snake-oil salesman.”

His case matters not because it’s representative — most wealthy longevity clients are not Bryan Johnson — but because it shows where optimization logic goes when nothing pushes back. If some data is good, more data must be better. If some intervention might help, try all of them at once.

---

The Gap Between Evidence and Commerce

This is where the story gets complicated.

The scientific evidence base for most commercially available longevity interventions is, to put it generously, incomplete. Much of it is extrapolated from animal studies that haven’t translated cleanly to humans. Some rests on observational data — correlations between certain biomarkers and outcomes — that don’t establish causation.

And some interventions simply haven’t been studied at the scale required to say much of anything with confidence.

Metformin is the clearest example. It’s an inexpensive, decades-old diabetes drug that drew interest as a potential anti-aging agent after epidemiological studies suggested that diabetic patients taking it seemed to outlive those who didn’t.

A large randomized human trial — the TAME trial, or Targeting Aging with Metformin, coordinated through Wake Forest University School of Medicine and backed by the NIH-funded Geroscience Network — has been underway to test whether metformin can actually delay age-related conditions like heart disease, cancer, and dementia in non-diabetic adults.

As of this writing, that trial remains ongoing, partially funded, and without published results. Which is another way of saying: we don’t know yet.

That gap — between what the science currently supports and what the market is actively selling — is precisely where this industry operates.

It operates there confidently, with language about “biological age reversal” and “healthspan optimization” that consistently outruns the evidence.

This is not to say the underlying science is fraudulent. Some of it is genuinely promising. Research on senolytics — drugs designed to selectively clear senescent cells, which accumulate with age and drive chronic inflammation — has shown meaningful results in animal models and in early-stage clinical trials.

According to Mordor Intelligence, patent filings in the longevity space jumped roughly 40% between 2022 and 2024, which suggests the industry believes something real is in the pipeline.

But believing something is in the pipeline is different from selling that future as a present reality. The premium many of these clinics charge is not really for proven outcomes. It’s for proximity to the frontier — and for the social signal that proximity carries.

---

What This Costs, and Who Pays

The equity implications of a tiered longevity market are not subtle.

Christopher Wareham, a bioethicist at Utrecht University, has argued that longevity science, if it succeeds, risks exacerbating the inequalities that already define healthcare. The mechanism is straightforward: effective longevity therapies will almost certainly be expensive at first. Access will follow wealth.

In the most serious version of this scenario, the result isn’t just that rich people live differently — it’s that they live meaningfully longer, with more time to accumulate wealth and influence. It would be a disparity not in how we die, but in when.

This anxiety rhymes with older debates about unequal access to organ transplants, to experimental cancer treatments, to the simply better primary care available to people with money. But aging is a universal condition in a way that a specific disease is not, which makes the stakes feel different.

Some in the longevity field take this seriously. The TAME trial’s focus on metformin — chosen in part precisely because it costs almost nothing per dose — reflects a genuine effort to develop interventions that could work at scale, not just for people who can afford a $15,000 annual membership. And some technologies that began in high-end clinics, like continuous glucose monitoring and liquid biopsy cancer screening, have been getting cheaper and more accessible over time. Technology has a track record of democratizing, eventually.

That word — eventually — is carrying a lot of weight. In the meantime, the market is structured almost entirely around people who can afford to treat their health the way they treat their finances: as a portfolio worth actively managing, with data, specialists, and capital.

---

The Silicon Valley Anthropology of Death

There is something worth sitting with in the particular intensity that tech culture has brought to this question.

Silicon Valley runs on a belief that any sufficiently motivated, well-funded effort can solve any problem. For most of tech history, that belief has been at least partially justified. But death is a different kind of problem.

It is not a system failure or a design flaw. Every serious philosophical and religious tradition humans have built — across every culture, over millennia — treats mortality not as a malfunction to be corrected but as the condition that makes a life meaningful in the first place. The fact that time runs out is inseparable from the reason that choices matter.

Peter Thiel’s declaration that death should be solved is a coherent position. It also sidesteps almost every hard question: What does radical life extension do to society? To politics? To the environment? To the meaning of a career, a family, a century?

The billionaires funding this research are, on the whole, not engaging with those questions. They are engaging with aging as an engineering problem, which means the parts of it they focus on are the parts that yield to engineering.

This is not a reason to dismiss the science. But it is a reason to hold the narrative carefully. There is a meaningful difference between research that might someday reduce suffering and extend healthy human years — which is genuinely valuable — and a consumer market that sells the aspiration of immortality to people with disposable income, dressed up in lab coats and data dashboards.

---

The Luxury That Doesn’t Call Itself Luxury

What makes longevity distinct from other premium markets is how it positions itself: not as indulgence, but as discipline. The language is always clinical — protocols, biomarkers, optimization, evidence-based interventions — because the aspiration isn’t to display wealth but to appear to have transcended the ordinary, inattentive relationship with the body that the rest of us muddle through.

That framing is itself a kind of luxury. The time required to track hundreds of biomarkers, follow precise dietary protocols, and show up for six-hour diagnostic visits is not available to most people regardless of whether they could afford the fee.

Longevity, at this level of commitment, requires not just money but the freedom from obligation that money makes possible.

There is something almost old-fashioned about it, for all the technology involved. The wealthy have always had more time to attend to their bodies — better food, less physical labor, less chronic stress, more sleep. The data infrastructure is new. The underlying dynamic is not.

What is genuinely new is the scale of the scientific ambitions attached to it, and the possibility — still uncertain, still years away — that some of what emerges from the labs will eventually be as transformative as its backers believe. If that happens, the question of who gets access first, and on what terms, will matter more than almost anything else about this industry.

That question is not being asked loudly enough yet. Which is, perhaps, the most telling thing about this moment.

---